search
Back to results

Post-Operative Radiotherapy De-Escalation of Negative Nodal Regions in Head and Neck Squamous Cell Carcinoma

Primary Purpose

Head and Neck Carcinoma

Status
Recruiting
Phase
Not Applicable
Locations
Egypt
Study Type
Interventional
Intervention
Elective nodal de-escalation arm
Sponsored by
National Cancer Institute, Egypt
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Head and Neck Carcinoma focused on measuring Post operative radiotherapy, Elective nodal irradiation, Head and neck SCC, Elective nodal omission, De-escalation

Eligibility Criteria

18 Years - 78 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Patients with a Karnofsky performance score of 70% or more. Completely or partially resected head and neck SCC. This includes: The oral cavity (lips, buccal mucosa, oral tongue, floor of mouth, gingiva, retromolar trigone, and hard palate), maxilla, oropharynx, and larynx. Patients with at least an ipsilateral neck dissection. Patient has at least one pathological feature that is an indication for PORT: positive or close (<5 mm) margin, presence of LVI or PNI, pT3 or pT4 disease, positive lymph nodes, or ENE. Pathologically lymph node negative in at least one dissected hemi-neck or PET-CT Exclusion Criteria: Patients with bilaterally involved neck nodes Patients with pT3-T4 tumors involving midline who undergo an ipsilateral neck dissection (unless a contralateral neck dissection is performed) Serious medical comorbidities or other contraindications to radiotherapy Prior history of head and neck cancer within 5 years Any other active invasive malignancy Prior head and neck radiation at any time Prior oncologic head and neck surgery in the oral cavity or neck. Known metastatic disease Locoregional disease recurrence identified following surgical resection but prior to start of radiotherapy Inability to attend full course of radiotherapy or follow-up visits 11.Unable or unwilling to complete QoL questionnaires

Sites / Locations

  • National Cancer InstituteRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Elective nodal de-escalation arm

Arm Description

Omission of elective nodal irradiation in N0 hemi-neck of well lateralized H&N SCCs ( pN0 or by PETCT). Dose de-escalation of elective nodal irradiation in N0 hemi-neck of midline H&N SCCs ( pN0 or by PETCT).

Outcomes

Primary Outcome Measures

Regional failure in the omitted/de-escalated elective nodal irradiation site

Secondary Outcome Measures

Acute toxicity
Late toxicity
Overall survival

Full Information

First Posted
December 6, 2022
Last Updated
December 6, 2022
Sponsor
National Cancer Institute, Egypt
search

1. Study Identification

Unique Protocol Identification Number
NCT05650034
Brief Title
Post-Operative Radiotherapy De-Escalation of Negative Nodal Regions in Head and Neck Squamous Cell Carcinoma
Official Title
Post-Operative Radiotherapy De-Escalation of Negative Nodal Regions in Head and Neck Squamous Cell Carcinoma
Study Type
Interventional

2. Study Status

Record Verification Date
September 2022
Overall Recruitment Status
Recruiting
Study Start Date
April 15, 2021 (Actual)
Primary Completion Date
December 2023 (Anticipated)
Study Completion Date
December 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
National Cancer Institute, Egypt

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
This is a non-randomized prospective trial evaluating the non- inferiority of de-escalating the volume and/or dose of elective nodal irradiation in post-operative head and neck squamous cell carcinomas.
Detailed Description
This is a non-randomized prospective trial evaluating the non-inferiority of volume and/or dose de-escalation of elective nodal irradiation in post-operative head and neck squamous cell carcinomas with assessment of toxicity profiles. 57 head and neck squamous cell carcinoma cases eligible for post-operative radiotherapy will be recruited and managed according to tumor laterality, nodal status, and laterality of nodal dissection (ipsilateral/ bilateral nodal dissection). Ipsilateral nodal dissection: If ipsilateral N0, bilateral nodal irradiation will be omitted. If ipsilateral N positive and tumor was well lateralized, contralateral nodal negativity will be assessed by PETCT. IF PETCT is free, the ipsilateral nodal regions will be irradiated with conventional doses while the contralateral nodal irradiation will be omitted. If ipsilateral N positive and tumor was not well lateralized, ipsilateral nodal regions will be irradiated with conventional doses while the contralateral nodal irradiation will be de-escalated to 40 Gy dose equivalent. Cases with PETCT positive for malignancy will be excluded from the study. Bilateral nodal dissection: If bilateral N0, bilateral nodal irradiation will be omitted. If one sided N positive, laterality of the tumor will be assessed: In well lateralized tumors, the positive side nodal regions will be irradiated while the contralateral nodal irradiation will be omitted. In midline/ non lateralized tumor the positive side nodal regions will be irradiated with conventional doses while the contralateral nodal irradiation will be de-escalated to 40 Gy dose equivalent. If bilateral N positive, cases will be excluded from the study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Head and Neck Carcinoma
Keywords
Post operative radiotherapy, Elective nodal irradiation, Head and neck SCC, Elective nodal omission, De-escalation

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
57 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Elective nodal de-escalation arm
Arm Type
Experimental
Arm Description
Omission of elective nodal irradiation in N0 hemi-neck of well lateralized H&N SCCs ( pN0 or by PETCT). Dose de-escalation of elective nodal irradiation in N0 hemi-neck of midline H&N SCCs ( pN0 or by PETCT).
Intervention Type
Radiation
Intervention Name(s)
Elective nodal de-escalation arm
Intervention Description
Omission of elective nodal irradiation in N0 hemi-neck of well lateralized H&N SCCs ( pN0 or by PETCT). Dose de-escalation of elective nodal irradiation in N0 hemi-neck of midline H&N SCCs ( pN0 or by PETCT).
Primary Outcome Measure Information:
Title
Regional failure in the omitted/de-escalated elective nodal irradiation site
Time Frame
Baseline to 1 year
Secondary Outcome Measure Information:
Title
Acute toxicity
Time Frame
Baseline to 6 months
Title
Late toxicity
Time Frame
Baseline to 1 year
Title
Overall survival
Time Frame
Baseline to 2 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
78 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with a Karnofsky performance score of 70% or more. Completely or partially resected head and neck SCC. This includes: The oral cavity (lips, buccal mucosa, oral tongue, floor of mouth, gingiva, retromolar trigone, and hard palate), maxilla, oropharynx, and larynx. Patients with at least an ipsilateral neck dissection. Patient has at least one pathological feature that is an indication for PORT: positive or close (<5 mm) margin, presence of LVI or PNI, pT3 or pT4 disease, positive lymph nodes, or ENE. Pathologically lymph node negative in at least one dissected hemi-neck or PET-CT Exclusion Criteria: Patients with bilaterally involved neck nodes Patients with pT3-T4 tumors involving midline who undergo an ipsilateral neck dissection (unless a contralateral neck dissection is performed) Serious medical comorbidities or other contraindications to radiotherapy Prior history of head and neck cancer within 5 years Any other active invasive malignancy Prior head and neck radiation at any time Prior oncologic head and neck surgery in the oral cavity or neck. Known metastatic disease Locoregional disease recurrence identified following surgical resection but prior to start of radiotherapy Inability to attend full course of radiotherapy or follow-up visits 11.Unable or unwilling to complete QoL questionnaires
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Sara A Elsharkawy
Phone
+20 2 2368 4423
Email
Sara.elsharkawy@nci.cu.edu.eg
First Name & Middle Initial & Last Name or Official Title & Degree
May Ashour
Email
May25s@hotmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Tarek Shouman
Organizational Affiliation
National Cancer Institute, Egypt
Official's Role
Study Director
Facility Information:
Facility Name
National Cancer Institute
City
Cairo
ZIP/Postal Code
11796
Country
Egypt
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sara Elsharkawy

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Post-Operative Radiotherapy De-Escalation of Negative Nodal Regions in Head and Neck Squamous Cell Carcinoma

We'll reach out to this number within 24 hrs